🎗️ Endometrial Cancer FIGO 2023 Stage (with molecular)
UseStaging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
SourceBerek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009.
When to use
Staging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
How it works
Non-aggressive (G1–2 endometrioid): IA no/< ½ MI, IB ≥ ½, IIA cervical stroma, IIB substantial LVSI. Aggressive: IC confined, IIC any MI. III/IV by anatomic extension. Molecular changes early confined disease only: POLEmut → IAmPOLEmut, p53abn + MI → IICmp53abn.
Key points
- FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009.
- MMRd and NSMP are recorded as subscripts but do not change the stage; for stage III/IV molecular subtype is recorded only.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Histologic type | Non-aggressive (G1–2 endometrioid) |
|---|---|
| Anatomic extent | Adnexa / uterine serosa (IIIA) |
| Molecular subtype | MMRd |
→FIGO stageStage IIIAmMMRd
- FIGO 2023 stage：Stage IIIAmMMRd (MMRd/NSMP do not change the stage, recorded as a subscript only; for stage III/IV the molecular subtype is recorded only)
- Management direction：Treatment follows current guidelines and multidisciplinary discussion; this page provides only staging and molecular classification.
- Notes：FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); for stage III/IV molecular subtype does not change the stage
| Histologic type | Non-aggressive (G1–2 endometrioid) |
|---|---|
| Anatomic extent | Confined to endometrium/polyp, no myometrial invasion |
| Molecular subtype | Unknown / not done |
→FIGO stageStage IA
- FIGO 2023 stage：Stage IA
- Management direction：Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
- Notes：FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); for stage III/IV molecular subtype does not change the stage
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Endometrial Cancer FIGO 2023 Stage (with molecular)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Endometrial Cancer FIGO 2023 Stage (with molecular) upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is Endometrial Cancer FIGO 2023 Stage (with molecular) calculated in practice? Can you show a worked example?
- Inputs: Histologic type Non-aggressive (G1–2 endometrioid), Anatomic extent Adnexa / uterine serosa (IIIA), Molecular subtype MMRd → Result: FIGO stage Stage IIIAmMMRd（FIGO 2023 stage: Stage IIIAmMMRd (MMRd/NSMP do not change the stage, recorded as a subscript only; for stage III/IV the molecular subtype is recorded only), Management direction: Treatment follows current guidelines and multidisciplinary discussion; this page provides only staging and molecular classification., Notes: FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); for stage III/IV molecular subtype does not change the stage） Inputs: Histologic type Non-aggressive (G1–2 endometrioid), Anatomic extent Confined to endometrium/polyp, no myometrial invasion, Molecular subtype Unknown / not done → Result: FIGO stage Stage IA（FIGO 2023 stage: Stage IA, Management direction: Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts., Notes: FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); for stage III/IV molecular subtype does not change the stage）